Business Wire

Appili Therapeutics Completes Phase 1 Study for ATI-1501, Its Taste-Masked Oral Metronidazole Suspension, Demonstrating Significant Improvements in Taste and Palatability

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (the “Company” or “Appili”) announced today positive top-line results of a pivotal relative bioavailability study evaluating ...
Yahoo Finance

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

WAYNE, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...
The Globe and Mail

Aclaris Therapeutics’ ATI-045 Study: A Potential Game-Changer for Atopic Dermatitis

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Study Overview: Aclaris Therapeutics Inc.
Nasdaq

Aclaris Therapeutics Reports Positive Top-line Results From Phase 2b ATI-1777-AD-202 Study

(RTTNews) - Aclaris Therapeutics, Inc. (ACRS) Wednesday announced positive top-line results from the Phase 2b ATI-1777-AD-202 study of ATI-1777 in patients with mild to severe atopic dermatitis. The ...